462 related articles for article (PubMed ID: 29330929)
1. Adipocytes affect castration-resistant prostate cancer cells to develop the resistance to cytotoxic action of NK cells with alterations of PD-L1/NKG2D ligand levels in tumor cells.
Xu L; Shen M; Chen X; Zhu R; Yang DR; Tsai Y; Keng PC; Chen Y; Lee SO
Prostate; 2018 Apr; 78(5):353-364. PubMed ID: 29330929
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of IL-6-JAK/Stat3 signaling in castration-resistant prostate cancer cells enhances the NK cell-mediated cytotoxicity via alteration of PD-L1/NKG2D ligand levels.
Xu L; Chen X; Shen M; Yang DR; Fang L; Weng G; Tsai Y; Keng PC; Chen Y; Lee SO
Mol Oncol; 2018 Mar; 12(3):269-286. PubMed ID: 28865178
[TBL] [Abstract][Full Text] [Related]
3. In vitro-induced M2 type macrophages induces the resistance of prostate cancer cells to cytotoxic action of NK cells.
Xu L; Shen M; Chen X; Yang DR; Tsai Y; Keng PC; Lee SO; Chen Y
Exp Cell Res; 2018 Mar; 364(1):113-123. PubMed ID: 29408565
[TBL] [Abstract][Full Text] [Related]
4. Combined inhibition of JAK1,2/Stat3‑PD‑L1 signaling pathway suppresses the immune escape of castration‑resistant prostate cancer to NK cells in hypoxia.
Xu LJ; Ma Q; Zhu J; Li J; Xue BX; Gao J; Sun CY; Zang YC; Zhou YB; Yang DR; Shan YX
Mol Med Rep; 2018 Jun; 17(6):8111-8120. PubMed ID: 29693186
[TBL] [Abstract][Full Text] [Related]
5. Increased infiltration of macrophages to radioresistant lung cancer cells contributes to the development of the additional resistance of tumor cells to the cytotoxic effects of NK cells.
Shen M; Chen Y; Xu L; Zhu R; Xue X; Tsai Y; Keng PC; Lee SO; Chen Y
Int J Oncol; 2018 Jul; 53(1):317-328. PubMed ID: 29750425
[TBL] [Abstract][Full Text] [Related]
6. A Crosstalk Between Castration-Resistant Prostate Cancer Cells, M2 Macrophages, and NK Cells: Role of the ATM-PI3K/AKT-PD-L1 Pathway.
Jin H; Zhu J; Xuan R; Zhou Y; Xue B; Yang D; Gao J; Zang Y; Xu L
Immunol Invest; 2023 Nov; 52(8):941-965. PubMed ID: 37732622
[TBL] [Abstract][Full Text] [Related]
7. Combined treatment with anti-PSMA CAR NK-92 cell and anti-PD-L1 monoclonal antibody enhances the antitumour efficacy against castration-resistant prostate cancer.
Wang F; Wu L; Yin L; Shi H; Gu Y; Xing N
Clin Transl Med; 2022 Jun; 12(6):e901. PubMed ID: 35696531
[TBL] [Abstract][Full Text] [Related]
8. Adipocyte-derived IL-6 and leptin promote breast Cancer metastasis via upregulation of Lysyl Hydroxylase-2 expression.
He JY; Wei XH; Li SJ; Liu Y; Hu HL; Li ZZ; Kuang XH; Wang L; Shi X; Yuan ST; Sun L
Cell Commun Signal; 2018 Dec; 16(1):100. PubMed ID: 30563531
[TBL] [Abstract][Full Text] [Related]
9. Docetaxel suppresses immunotherapy efficacy of natural killer cells toward castration-resistant prostate cancer cells via altering androgen receptor-lectin-like transcript 1 signals.
Tang M; Gao S; Zhang L; Liu B; Li J; Wang Z; Zhang W
Prostate; 2020 Jul; 80(10):742-752. PubMed ID: 32449811
[TBL] [Abstract][Full Text] [Related]
10. Enhancing NK cell-mediated cytotoxicity to cisplatin-resistant lung cancer cells via MEK/Erk signaling inhibition.
Yang L; Shen M; Xu LJ; Yang X; Tsai Y; Keng PC; Chen Y; Lee SO
Sci Rep; 2017 Aug; 7(1):7958. PubMed ID: 28801607
[TBL] [Abstract][Full Text] [Related]
11. PD-L1 induced by IFN-γ from tumor-associated macrophages via the JAK/STAT3 and PI3K/AKT signaling pathways promoted progression of lung cancer.
Zhang X; Zeng Y; Qu Q; Zhu J; Liu Z; Ning W; Zeng H; Zhang N; Du W; Chen C; Huang JA
Int J Clin Oncol; 2017 Dec; 22(6):1026-1033. PubMed ID: 28748356
[TBL] [Abstract][Full Text] [Related]
12. Prostate tumor-derived exosomes down-regulate NKG2D expression on natural killer cells and CD8+ T cells: mechanism of immune evasion.
Lundholm M; Schröder M; Nagaeva O; Baranov V; Widmark A; Mincheva-Nilsson L; Wikström P
PLoS One; 2014; 9(9):e108925. PubMed ID: 25268476
[TBL] [Abstract][Full Text] [Related]
13. Effect of platinum‑based chemotherapy on the expression of natural killer group 2 member D ligands, programmed cell death‑1 ligand 1 and HLA class I in non‑small cell lung cancer.
Okita R; Maeda A; Shimizu K; Nojima Y; Saisho S; Nakata M
Oncol Rep; 2019 Aug; 42(2):839-848. PubMed ID: 31173242
[TBL] [Abstract][Full Text] [Related]
14. STAT3 contributes to NK cell recognition by modulating expression of NKG2D ligands in adriamycin-resistant K562/AO2 cells.
Cai X; Lu X; Jia Z; Zhang X; Han W; Rong X; Ma L; Zhou M; Chen B
Int J Hematol; 2015 Nov; 102(5):536-43. PubMed ID: 26387089
[TBL] [Abstract][Full Text] [Related]
15. ATM‑JAK‑PD‑L1 signaling pathway inhibition decreases EMT and metastasis of androgen‑independent prostate cancer.
Zhang L; Xu LJ; Zhu J; Li J; Xue BX; Gao J; Sun CY; Zang YC; Zhou YB; Yang DR; Shan YX
Mol Med Rep; 2018 May; 17(5):7045-7054. PubMed ID: 29568923
[TBL] [Abstract][Full Text] [Related]
16. Radiation alters PD-L1/NKG2D ligand levels in lung cancer cells and leads to immune escape from NK cell cytotoxicity via IL-6-MEK/Erk signaling pathway.
Shen MJ; Xu LJ; Yang L; Tsai Y; Keng PC; Chen Y; Lee SO; Chen Y
Oncotarget; 2017 Oct; 8(46):80506-80520. PubMed ID: 29113321
[TBL] [Abstract][Full Text] [Related]
17. FASN-TGF-β1-PD-L1 axis contributes to the development of resistance to NK cell cytotoxicity of cisplatin-resistant lung cancer cells.
Shen M; Tsai Y; Zhu R; Keng PC; Chen Y; Chen Y; Lee SO
Biochim Biophys Acta Mol Cell Biol Lipids; 2018 Mar; 1863(3):313-322. PubMed ID: 29306075
[TBL] [Abstract][Full Text] [Related]
18. Potentiation of NK cell-mediated cytotoxicity in human lung adenocarcinoma: role of NKG2D-dependent pathway.
Le Maux Chansac B; Missé D; Richon C; Vergnon I; Kubin M; Soria JC; Moretta A; Chouaib S; Mami-Chouaib F
Int Immunol; 2008 Jul; 20(7):801-10. PubMed ID: 18441340
[TBL] [Abstract][Full Text] [Related]
19. Rae1 drives NKG2D binding-dependent tumor development in mice by activating mTOR and STAT3 pathways in tumor cells.
Zhao P; Yang L; Li X; Lu W; Lu F; Wang S; Wang Y; Hua L; Cui C; Dong B; Yu Y; Wang L
Cancer Sci; 2020 Jul; 111(7):2234-2247. PubMed ID: 32333709
[TBL] [Abstract][Full Text] [Related]
20. Implication of combined PD-L1/PD-1 blockade with cytokine-induced killer cells as a synergistic immunotherapy for gastrointestinal cancer.
Dai C; Lin F; Geng R; Ge X; Tang W; Chang J; Wu Z; Liu X; Lin Y; Zhang Z; Li J
Oncotarget; 2016 Mar; 7(9):10332-44. PubMed ID: 26871284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]